Competing interests
This was an independent, investigator-initiated study supported by Boehringer Ingelheim (BI) Pharma GmbH & Co. KG, Germany. BI had no role in the design, analysis or interpretation of the results in this study. BI was given the opportunity to review the manuscript for medical and scientific accuracy as it relates to BI substance, as well as intellectual property considerations. J.G. received honoraria from TESARO, QUIRIS Healthcare, Ecker + Ecker, Dr. August Wolff, Roche, University Clinics Schleswig–Holstein, and RWTH Aachen University. J.-H.M. received honoraria from Astellas, Pfizer, Daiichi Sankyo, BMS, Celgene, Novartis, Jazz, and BeiGene. G.L. received research grants not related to this manuscript from AGIOS, AQUINOX, AstraZeneca, Bayer, Celgene, Gilead, Janssen, Morphosys, Novartis, Roche, and Verastem. G.L. received honoraria from ADC Therapeutics, Abbvie, Amgen, AstraZeneca, Bayer, BMS, Celgene, Constellation, Genmab, Gilead, Incyte, Janssen, Karyopharm, Miltenyi, Morphosys, NanoString, Novartis, and Roche. C.S. received honoraria from AbbVie, AstraZeneca, Astellas, BMS, Celgene, Jazz, Novartis, Pfizer and Roche. The remaining authors declare no competing financial interests. 